Dyslipidemia is when the lipids in your blood are too high or too low. Estimates suggest that 53 percent of adults in the U.S. have lipid abnormalities. Lipids are a type of fat that make up the ...

The Gemini Study was a 14-week, open-label, non-comparative, office-based, multicenter trial to evaluate single-pill therapy in the treatment of concomitant hypertension and dyslipidemia. In addition ...

Dyslipidemia is when the lipids in your blood are too high or too low. Estimates suggest that 53 percent of adults in the U.S. have lipid abnormalities. Lipids are a type of fat that make up the ...

Atherosclerosis represents a disease that begins in childhood, and alterations in lipid concentration play a fundamental role in the development of this condition. Children and adolescents with high ...

An animal study has found that metformin effectively ameliorate the development of risperidone-induced insulin resistance and dyslipidemia (that is, altered serum triglyceride and total cholesterol ...

Abbott (Abbott Park, Ill.) and AstraZeneca (London, UK) have submitted a New Drug Application (NDA) for an investigational drug to treat mixed dyslipidemia. Pending approval of the NDA, the drug will ...

Consistently elevated lipids and dyslipidemia in early life were associated with worsening subclinical atherosclerosis, but simulated lipid treatment in late adolescence stopped atherosclerosis ...

Dyslipidemia describes abnormal levels of fatty compounds in your blood known as lipids that can contribute to your risk of heart disease. The main goal of treatment is to lower low-density ...

JUPITER Trial Results, Advantages in Efficacy and Fall Out from Vytorin and Zetia are Likely Drivers of Increased Patient Share for Crestor, According to a New Report from Decision Resources ...

LONDON, UK (GlobalData), 19 May 2015 - The global treatment market for dyslipidemia will more than double in value from $15.4 billion in 2013 to an estimated $37.9 billion by 2023, representing a ...